Fig. 1 · Structure
Documents & Downloads
Sofituzumab vedotin
Anti-MUC16 ADC
Sofituzumab vedotin is an antibody-drug conjugate (ADC) targeting MUC16, linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This compound exhibits potent anti-cancer activity by delivering MMAE selectively to MUC16-expressing tumor cells, thereby inhibiting their proliferation. It serves as a valuable tool in cancer research, particularly in the exploration of targeted therapies for malignancies associated with MUC16 overexpression.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1418200-58-4 |
| Applications | Anti-MUC16 ADC |
| Molecular Weight | 144000 (average) |
| Synonyms | DMUC5754A |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.